Increased plasma levels of matrix metalloproteinase-9 in patients with Alzheimer's disease

Neurochemistry International

Volumn 43, Issue 3, 2003, Pages 191-196

  Lorenzl, Stefan ^a   Albers, David S ^a   Relkin, Norman ^a   Ngyuen, Terry ^a   Hilgenberg, Sarah L ^b   Chirichigno, Jason ^a   Cudkowicz, Merit E ^b   Beal, M Flint ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Alzheimer's disease; Amyotrophic lateral sclerosis; Matrix metalloproteinases; Parkinson's disease; Tissue inhibitors of metalloproteinases

Indexed keywords

APOLIPOPROTEIN E; GELATINASE A; GELATINASE B; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ADULT; AGED; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; STATISTICAL ANALYSIS; WESTERN BLOTTING; ZYMOGRAPHY;

EID: 0037411793     PISSN: 01970186     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0197-0186(03)00004-4     Document Type: Article

References (34)

1. Albers D.S., Beal M.F. Mitochondrial dysfunction and oxidative stress in aging and neurodegenerative. J. Neural Trans. Suppl. 59:2000;133-154.
2. Asahi M., Asahi K., Jung J.C., del Zoppo G.J., Fini M.E., Lo E.H. Role for matrix metalloproteinase-9 after focal cerebral ischemia: effects of gene knockout and enzyme inhibition with BB-94. J. Cereb. Blood Flow Metab. 20:2000;1681-1689.
3. Asahi M., Wang X., Mori T., Sumii T., Jung J.C., Moskowitz M.A., Fini M.E., Lo E.H. Effects of matrix metalloproteinase-9 gene knock-out on the proteolysis of blood-brain barrier and white matter components after cerebral ischemia. J. Neurosci. 21:2001;7724-7732.
4. Asahina M., Yoshiyama Y., Hattori T. Expression of matrix metalloproteinase-9 and urinary-type plasminogen activator in Alzheimer's disease brain. Clin. Neuropathol. 20:2001;60-63.
5. Backstrom J.R., Miller C.A., Tokes Z.A. Characterization of neutral proteinases from Alzheimer-affected and control brain specimens: identification of calcium-dependent metalloproteinases from the hippocampus. J. Neurochem. 58:1992;983-992.
6. Backstrom J.R., Lim G.P., Cullen M.J., Tokes Z.A. Matrix metalloproteinase-9 (MMP-9) is synthesized in neurons of the human hippocampus and is capable of degrading the amyloid-beta peptide (1-40). J. Neurosci. 16:1996;7910-7919.
7. Beuche W., Yushchenko M., Mader M., Maliszewska M., Felgenhauer K., Weber F. Matrix metalloproteinase-9 is elevated in serum of patients with amyotrophic lateral sclerosis. Neuroreport. 11:2000;3419-3422.
8. Bogdanov M., Brown R.H., Matson W., Smart R., Hayden D., O'Donnell H., Flint Beal M., Cudkowicz M. Increased oxidative damage to DNA in ALS patients. Free Radic. Biol. Med. 29:2000;652-658.
9. Brew K., Dinakarpandian D., Nagase H. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim. Biophys. Acta. 1477:2000;267-283.
10. Brooks B.R. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial "Clinical limits of amyotrophic lateral sclerosis" workshop contributors. J. Neurol. Sci. 124(Suppl.):1994;96-107.
11. Chong Y.H., Sung J.H., Shin S.A., Chung J.H., Suh Y.H. Effects of the beta-amyloid and carboxyl-terminal fragment of Alzheimer's amyloid precursor protein on the production of the tumor necrosis factor-alpha and matrix metalloproteinase-9 by human monocytic THP-1. J. Biol. Chem. 276:2001;23511-23517.
12. Clark A.W., Krekoski C.A., Bou S.S., Chapman K.R., Edwards D.R. Increased gelatinase A (MMP-2) and gelatinase B (MMP-9) activities in human brain after focal ischemia. Neurosci. Lett. 238:1997;53-56.
13. Gottschall P.E., Deb S. Regulation of matrix metalloproteinase expressions in astrocytes, microglia and neurons. Neuroimmunomodulation. 3:1996;69-75.
14. Hoehn M.M., Yahr M.D. Parkinsonism: onset, progression and mortality. Neurology. 17:1967;427-442.
15. Hofmann M.A., Lalla E., Lu Y., Gleason M.R., Wolf B.M., Tanji N., Ferran L.J., Kohl B., Rao V., Kisiel W., Stern D.M., Schmidt A.M. Hyperhomocysteinemia enhances vascular inflammation and accelerates atherosclerosis in a murine model. J. Clin. Invest. 107:2001;675-683.
16. Jordan B.D., Relkin N.R., Ravdin L.D., Jacobs A.R., Bennett A., Gandy S. Apolipoprotein E epsilon4 associated with chronic traumatic brain injury in boxing. J. Am. Med. Assoc. 278:1997;136-140.
17. Kolb S.A., Lahrtz F., Paul R., Leppert D., Nadal D., Pfister H.W., Fontana A. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in viral meningitis: upregulation of MMP-9 and TIMP-1 in cerebrospinal fluid. J. Neuroimmunol. 84:1998;143-150.
18. LePage R.N., Fosang A.J., Fuller S.J., Murphy G., Evin G., Beyreuther K., Masters C.L., Small D.H. Gelatinase A possesses a beta-secretase-like activity in cleaving the amyloid protein precursor of Alzheimer's disease. FEBS Lett. 377:1995;267-270.
19. Leppert D., Ford J., Stabler G., Grygar C., Lienert C., Huber S., Miller K.M., Hauser S.L., Kappos L. Matrix metalloproteinase-9 (gelatinase B) is selectively elevated in CSF during relapses and stable phases of multiple sclerosis. Brain. 121:1998;2327-2334.
20. McGeer P.L., McGeer E.G. Mechanisms of cell death in Alzheimer's disease - immunopathology. J. Neural Trans. Suppl. 54:1998;159-166.
21. Miyazaki K., Hasegawa M., Funahashi K., Umeda M. A metalloproteinase inhibitor domain in Alzheimer amyloid protein precursor. Nature. 362:1993;839-841.
22. Moutsiakis D., Mancuso P., Krutzsch H., Stetler-Stevenson W., Zucker S. Characterization of metalloproteinases and tissue inhibitors of metalloproteinases in human plasma. Connect Tissue Res. 28:1992;213-230.
23. Mujumdar V.S., Aru G.M., Tyagi S.C. Induction of oxidative stress by homocyst(e)ine impairs endothelial function. J. Cell. Biochem. 82:2001;491-500.
24. Okamoto T., Akaike T., Sawa T., Miyamoto Y., van der Vliet A., Maeda H. Activation of matrix metalloproteinases by peroxynitrite-induced protein S-glutathiolation via disulfide S-oxide formation. J. Biol. Chem. 276:2001;29596-29602.
25. Paul R., Lorenzl S., Koedel U., Sporer B., Vogel U., Frosch M., Pfister H.W. Matrix metalloproteinases contribute to the blood-brain barrier disruption during bacterial meningitis. Ann. Neurol. 44:1998;592-600.
26. Peress N., Perillo E., Zucker S. Localization of tissue inhibitor of matrix metalloproteinases in Alzheimer's disease and normal brain. J. Neuropathol. Exp. Neurol. 54:1995;16-22.
27. Pratico D., Clark C.M., Lee V.M., Trojanowski J.Q., Rokach J., FitzGerald G.A. Increased 8,12-iso-iPF2alpha-VI in Alzheimer's disease: correlation of a noninvasive index of lipid peroxidation with disease severity. Ann. Neurol. 48:2000;809-812.
28. Price J.L., Davis P.B., Morris J.C., White D.L. The distribution of tangles, plaques and related immunohistochemical markers in healthy aging and Alzheimer's disease. Neurobiol. Aging. 12:1991;295-312.
29. Pugin J., Widmer M.C., Kossodo S., Liang C.M., Preas H.L.n., Suffredini A.F. Human neutrophils secrete gelatinase B in vitro and in vivo in response to endotoxin and proinflammatory mediators. Am. J. Respir. Cell. Mol. 20:1999;458-464.
30. Sayre L.M., Smith M.A., Perry G. Chemistry and biochemistry of oxidative stress in neurodegenerative disease. Curr. Med. Chem. 8:2001;721-738.
31. Seshadri S., Beiser A., Selhub J., Jacques P.F., Rosenberg I.H., D'Agostino R.B., Wilson P.W., Wolf P.A. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N. Engl. J. Med. 346:2002;476-483.
32. Yong V.W., Power C., Forsyth P., Edwards D.R. Metalloproteinases in biology and pathology of the nervous system. Nat. Rev. Neurosci. 2:2001;502-511.
33. Yushchenko M., Weber F., Mader M., Scholl U., Maliszewska M., Tumani H., Felgenhauer K., Beuche W. Matrix metalloproteinase-9 (MMP-9) in human cerebrospinal fluid (CSF): elevated levels are primarily related to CSF cell count. J. Neuroimmunol. 110:2000;244-251.
34. Zucker S., Hymowitz M., Conner C., Zarrabi H.M., Hurewitz A.N., Matrisian L., Boyd D., Nicolson G., Montana S. Measurement of matrix metalloproteinases and tissue inhibitors of metalloproteinases in blood and tissues. Clinical and experimental applications. Ann. N. Y. Acad. Sci. 878:1999;212-227.